Alison Kanski

The researchers found biomarkers of macrophage activity and immune activity were associated with resistance and response to Opdivo plus Cabometyx.

The presence of primary resistance and KRAS G12C co-mutations may explain limited single-agent efficacy of marketed KRAS inhibitors, a recent study suggests.

In a recent trial, researchers found that Xpovio plus chemo had activity in NSCLC patients with KRAS mutations other than G12C.

Researchers explored how Pluvicto is used in the community and academic settings and when given by oncologists or urologists.

By analyzing ERBB2 mRNA expression data, researchers identified a group of HER2-negative patients with poor outcomes and potential markers of treatment resistance.

Researchers have been "making great inroads" in precision medicine, and a 15 percent cap on indirect costs could quash the momentum, experts worry.

Intravenous Opdivo, with $2.48 billion in sales, topped the list of precision oncology products in BMS's growth portfolio.

Sales of the firm's bispecific T-cell engager Blincyto increased more than 50 percent from the fourth quarter of 2023 to 2024.

The firm recorded Q4 oncology revenues of $4.06 billion compared to $3.19 billion in the same period in 2023.

Data presented at the ASCO Gastrointestinal Cancers Symposium showed the regimen may be a new option, but it comes with more treatment and financial toxicity.